Hogan Lovells advises Valneva on its initial public offering on the Nasdaq Global Select Market.
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.
Valneva announced the success of its initial public offering on the Nasdaq Global Select Market. This transaction enabled Valneva to raise approximately $107.6 million (approximately 89.6 million euros) through a capital increase of 8,145,176 new shares, of which 5,700,176 were delivered in the form of American Depositary Shares.
The Hogan Lovells team was led by Jean-Marc Franceschi (partner) and included Arnaud Deparday (Counsel), Madalina Asandului and Claudia Reix (associates).
